Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price

Kim, Hansoo; Goodall, Stephen; Liew, Danny

doi:10.1080/13696998.2021.1955540

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ICER is below the commonly acceptable willingness-to-pay (WTP) threshold of $75,000 per QALY for cost-effectiveness used in Australia. A WTP of $75,000 has previously been used in PBAC submissions in renal cell carcinoma [ 33 ], follicular lymphoma [ 34 ], and intraocular lens technology [ 35 ].…”

Section: Resultsmentioning

confidence: 99%

Cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for early treatment of adult lower limb spasticity following an acute event

Moore,

Danchenko,

Weidlich

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Objectives Spasticity is an incurable chronic condition, and patients with spasticity frequently experience symptoms such as muscle stiffness, restricted mobility, fatigue, spasms, and pain. The study objective was to assess the cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for the early treatment of adult lower limb spasticity following an acute event (e.g. stroke or traumatic brain injury), from an Australian payer perspective. Methods Using clinical data from published pivotal trials, an economic model based on a Markov model was developed to capture changes in treatment costs, healthcare resource use costs, functional outcomes, and health-related quality of life over a lifetime horizon. Scenario analyses and a probabilistic sensitivity analysis were conducted to explore the uncertainty in the model parameters and assumptions used in the base case. Results AbobotulinumtoxinA plus best supportive care was cost-effective versus best supportive care, yielding an incremental cost-effectiveness ratio of $35,721 per quality-adjusted life year gained. Sensitivity analyses confirm the robustness of the base case, with most results remaining below the commonly acceptable cost-effectiveness willingness-to-pay threshold of $75,000 per quality-adjusted life year for cost-effectiveness in Australia. Inputs and assumptions that produced the top four highest incremental cost-effectiveness ratios include the application of different health resource utilisation source, short time horizon, unweighted regression analyses to determine regression probabilities, and no stopping rule. AbobotulinumtoxinA plus best supportive care has a 74% probability of being cost-effective compared with best supportive care alone at the willingness to pay threshold. Conclusion AbobotulinumtoxinA plus best supportive care treatment is cost-effective in Australia for the management of adult lower limb spasticity in patients treated within 2 years of an acute event.

show abstract

Section: Resultsmentioning

confidence: 99%

Cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for early treatment of adult lower limb spasticity following an acute event

Moore,

Danchenko,

Weidlich

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…For comparison, our ICER for E-CPR is lower than that for some other expensive new medical technologies currently used in Australia such as pelvic exenteration (AUD 227,330 per QALY gained compared to without the intervention), 31 and nivolumab for the treatment of renal cell carcinoma (AUD 266,871 per QALY gained compared to everolimus). 32 …”

Section: Discussionmentioning

confidence: 99%